1-3 of 3
Rosemary Harrup, MB BS, FRACP, FRCPA
Close
Sort by
Journal Articles

Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily J Forsyth, MB BS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Melanie Sulda, B.Sc, PhD, Giles Best, BSc (Hons), PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone J Kuss, MBBS, PhD FRCPA, FRACP
Journal: Blood
Blood (2014) 124 (21): 4695.
https://doi.org/10.1182/blood.V124.21.4695.4695
Published: 2014
Journal Articles

A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS FRACP FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily J Forsyth, MB BS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Melanie Sulda, B.Sc, PhD, Giles Best, BSc (Hons), PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone J Kuss, MBBS, PhD FRCPA, FRACP
Journal: Blood
Blood (2014) 124 (21): 3325.
https://doi.org/10.1182/blood.V124.21.3325.3325
Published: 2014
Journal Articles

A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Devinder S Gill, MB ChB, MRCP (UK), FRCPath (Lond), Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS, FRACP, FRCPA, Leanne Berkahn, MB ChB, FRACP, FRCPA, David Simpson, FRACP, FRCPA, MBChB, Philip Campbell, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Marnie Collins, BCom, BSc(Hons), Paul Cortissos, Melanie Sulda, B.Sc, Ph.D., Giles Best, B.Sc., Ph.D., Bryone J Kuss, MBBS, PhD, FRCPA, FRACP
Journal: Blood
Blood (2012) 120 (21): 436.
https://doi.org/10.1182/blood.V120.21.436.436
Published: 2012